Pfizer seeks ways to ease adverse events reporting digitally

Share this article:
Pfizer seeks ways to ease adverse events reporting digitally
Pfizer seeks ways to ease adverse events reporting digitally
Pfizer is experimenting with electronic medical records and mobile technology to detect safety issues sooner.

The company is partnering with Sermo, Epocrates and Brigham and Women's Hospital in Boston on projects aimed at making it easier for doctors to report adverse events information or ask questions about Pfizer medications, according to a Dow Jones report.

A collaboration with Harvard-affiliated Brigham and Women's Hospital, codenamed “Aster (Adverse drug event Spontaneous Triggered Event Reporting),” uses automated prompts in the hospital's computer system to encourage adverse event reporting – when, for example, a doctor changes the dosage of a drug. That data is then automatically passed on to FDA and the companies. The system also collects more information about a patient's background in order to make it easier to determine whether an adverse event was caused by a drug or some other factor.

“We essentially demonstrated that you could make it easier for physicians to report adverse events thorough leveraging the electronic record,” Pfizer chief medical officer Freda Lewis-Hall told Dow Jones.

Pfizer has also placed a “contact manufacturer” button on Epocrates' mobile reference app, used by 275,000 physicians, which allows them to contact Pfizer's medical affairs department directly, via phone or email, to ask questions about Pfizer products. Companies can segment that feature, said an Epocrates spokeswoman, so that it only appears to, say, high-decile prescribers (though Pfizer doesn't do so).

Similarly, Sermo has added a feature making it easier for its physician members to contact Pfizer with questions about its medicines.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...